Torgrim Tandstad

Torgrim Tandstad serves as Associate Professor in the Department of Clinical and Molecular Medicine at the Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), and concurrently holds a Senior Consultant Oncology position at St. Olavs Hospital's Gastrosenteret in Trondheim.

His research program centers on testicular cancer survivorship and germ cell tumor management, with significant emphasis on:

• Long-term treatment complications including second malignancies and hormonal deficiencies
• Risk stratification models for relapse prediction in nonseminomatous tumors
• Novel biomarker development (particularly miR-371a-3p) for viable tumor detection
• Population-based outcomes analysis through binational Scandinavian collaborations
• Radiotherapy and chemotherapy toxicity profiles in survivorship cohorts

Analysis of his 2021-2025 publications reveals sustained leadership in testicular cancer research, characterized by validation of post-chemotherapy fibrosis prediction models, investigation of PSMA-based imaging for prostate cancer recurrence, and active participation in the IGCCCG Update Consortium. His work consistently leverages large population datasets from the Swedish Norwegian Testicular Cancer Group (SWENOTECA) to address critical gaps in evidence-based management.

Scientific Awards:

• No specific awards documented in source materials

Dr. Tandstad's clinical trial leadership (notably the SPCG 19/GRand-P prostate cancer study) indicates substantial grant funding, while his dual academic-clinical role implies ongoing mentorship of medical trainees despite absence of enumerated students in provided documentation.

He functions as a core investigator within the Swedish Norwegian Testicular Cancer Group (SWENOTECA), contributing to protocol development for nationwide testicular cancer management across Scandinavia.